drugset / Trial / NCT05508594

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

NCT05508594

Phase 2/3 Completed 220 enrolled Cessatech A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomised, double-blind, parallel-group, study comparing the analgesic effect of intranasal CT001 to intranasal sufentanil, intranasal ketamine or placebo for treatment of acute pain in adults undergoing surgical removal of an impacted mandibular third molar, where bone removal is judged to be needed.

Timeline

Start
2022-09-05
Primary completion
2023-10-05
Completion
2023-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CT001 Unknown Intranasal
Comparator Ketamine Small molecule 13 mg Intranasal
Comparator Ketamine Small molecule 27 mg Intranasal
Comparator Ketamine Small molecule 40 mg Intranasal
Comparator Sufentanil Other / unclassified 13 ug Intranasal
Comparator Sufentanil Other / unclassified 27 ug Intranasal
Comparator Sufentanil Other / unclassified 40 ug Intranasal

Indications

No indication recorded.